Pfizer Inks Diabetes Discovery Collaboration With Sanford-Burnham
This article was originally published in The Pink Sheet Daily
Executive Summary
The New York-based pharma continues to delve further into the diabetes research space despite not currently having a commercial presence in the therapeutic area. Pfizer’s latest tie-up will help it identify targets that could be used in the treatment of diabetes and obesity.